share_log

Reneo Pharmaceuticals | 10-K/A: Annual report (Amendment)

SEC announcement ·  Apr 26 06:18
Summary by Moomoo AI
Reneo Pharmaceuticals, Inc. (Reneo Pharmaceuticals), a clinical-stage pharmaceutical company, has filed an amended annual report (Form 10-K/A) with the U.S. Securities and Exchange Commission (SEC) for the fiscal year ended December 31, 2023. The amendment includes information required by Part III of Form 10-K, which was previously omitted from the original filing. The company has stated that the amendment does not modify or update any previously reported financial results nor does it change any financial statements. The filing includes details about the company's directors, executive officers, and corporate governance, as well as executive compensation and equity ownership among certain beneficial owners and management. Reneo Pharmaceuticals' common stock is registered under the symbol RPHM and is traded on The...Show More
Reneo Pharmaceuticals, Inc. (Reneo Pharmaceuticals), a clinical-stage pharmaceutical company, has filed an amended annual report (Form 10-K/A) with the U.S. Securities and Exchange Commission (SEC) for the fiscal year ended December 31, 2023. The amendment includes information required by Part III of Form 10-K, which was previously omitted from the original filing. The company has stated that the amendment does not modify or update any previously reported financial results nor does it change any financial statements. The filing includes details about the company's directors, executive officers, and corporate governance, as well as executive compensation and equity ownership among certain beneficial owners and management. Reneo Pharmaceuticals' common stock is registered under the symbol RPHM and is traded on The Nasdaq Stock Market LLC. The company's shares are held by a number of significant investors, including entities affiliated with New Enterprise Associates, Tang Capital Partners, LP, and Abingworth Bioventures 8 LP. The company has also entered into indemnification agreements with its directors and executive officers and maintains a severance benefit plan for its named executive officers. The filing confirms that the majority of the company's board members are independent as defined by Nasdaq Listing Rules. Ernst & Young LLP serves as the company's independent registered public accounting firm.

This announcement is a separate document:

Doc 1

Doc 2

Doc 3

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more